Rate Video

ESH AL 2018 | FLT3 inhibitors in the treatment of AML

Farhad Ravandi • 4 May 2018

ESH AL 2018

Acute Myeloid Leukemia Leukemia Azacitidine Crenolanib Gilteritinib Midostaurin Quizartinib Sorafenib

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes which FLT3 inhibitors his group uses to treat different subsets of patients with acute myeloid leukemia (AML ). This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Ponatinib, venetoclax and dexamethasone in R/R Ph+ ALL

Farhad Ravandi • 10 Dec 2020

Triple therapy including nivolumab for newly diagnosed AML

Farhad Ravandi • 9 Dec 2017

Prolonging remission in AML

Farhad Ravandi • 11 Mar 2021

Hyper-CVAD with NEL and PEG in T-ALL/LBL

Farhad Ravandi • 10 Dec 2020

Related Videos

Key challenges of using the intestinal microbiome as a biomarker

CAR T-cell therapy: the importance of LTFU

The future of AML therapy

Andreas Burchert

Treating pediatric patients with hematological malignancies

Claudia Rössig